Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 1/20 | 0.31 |
| ▸ | ELOC | Q15369 | 1/20 | 0.31 |
| ▸ | ELOB | Q15370 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29144771 | 0.91 | LPL (0.36) | LPLLIPGCA1CA2PRSS1 | |
| SCHEMBL14986013 | 0.82 | LPL (0.39) | LPLLIPGCA1CA2PRSS1 | |
| SCHEMBL5307244 | 0.81 | LPL (0.39) | LPLLIPGCA1CA2TRPV1 | |
| SCHEMBL5953336 | 0.79 | LPL (0.50) | LPLLIPGCA1CA2 | |
| SCHEMBL22536178 | 0.79 | ENPP2 (0.46) | LPLLIPGCA1CA2LTA4H | |
| SCHEMBL28504084 | 0.79 | LPL (0.40) | LPLLIPGCA1CA2PRSS1 | |
| SCHEMBL21253538 | 0.78 | ENPP2 (0.59) | LPLLIPGPRSS1PRSS2PRSS3 | |
| SCHEMBL21315979 | 0.78 | ORAI1 (0.48) | LPLLIPGTRPV1 | |
| SCHEMBL20283963 | 0.78 | LPL (0.34) | LPLLIPGCA1CA2ENPP2 | |
| SCHEMBL21449321 | 0.78 | ENPP2 (0.48) | LPLLIPGTSHRENPP2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LPL 723/4885LIPG 2233/4885CA1 4622/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LPL 723/4885LIPG 2233/4885CA1 4622/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LPL 723/4885LIPG 2233/4885CA1 4622/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LPL 723/4885LIPG 2233/4885CA1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.